Strs Ohio Cuts Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Strs Ohio trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 12.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,600 shares of the company’s stock after selling 800 shares during the period. Strs Ohio’s holdings in Krystal Biotech were worth $694,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in KRYS. China Universal Asset Management Co. Ltd. boosted its position in Krystal Biotech by 111.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after buying an additional 379 shares during the period. Fox Run Management L.L.C. bought a new position in shares of Krystal Biotech during the third quarter valued at about $219,000. Prime Capital Investment Advisors LLC bought a new position in shares of Krystal Biotech during the fourth quarter valued at about $310,000. Graham Capital Management L.P. bought a new position in shares of Krystal Biotech during the third quarter valued at about $330,000. Finally, Confluence Wealth Services Inc. raised its stake in shares of Krystal Biotech by 20.7% during the third quarter. Confluence Wealth Services Inc. now owns 2,920 shares of the company’s stock valued at $339,000 after acquiring an additional 500 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 8,087 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the completion of the transaction, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,719,041.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 8,087 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the sale, the chief accounting officer now owns 12,556 shares in the company, valued at approximately $1,719,041.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,087 shares of company stock valued at $6,210,591. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

KRYS stock opened at $155.68 on Friday. Krystal Biotech, Inc. has a 1 year low of $82.09 and a 1 year high of $189.97. The company has a market cap of $4.44 billion, a P/E ratio of 1,946.24 and a beta of 0.85. The firm has a 50-day moving average of $163.46 and a 200 day moving average of $131.32.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The company had revenue of $42.14 million during the quarter, compared to the consensus estimate of $27.43 million. During the same period in the previous year, the company earned ($1.25) earnings per share. On average, equities research analysts expect that Krystal Biotech, Inc. will post 1.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Guggenheim upped their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research note on Monday. Finally, Citigroup upped their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $171.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).